572 related articles for article (PubMed ID: 21853352)
41. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
42. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
[TBL] [Abstract][Full Text] [Related]
43. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
44. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
45. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
47. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy.
Zhou P; Gautam S; Recht A
Breast Cancer Res Treat; 2007 Jan; 101(1):51-7. PubMed ID: 16821084
[TBL] [Abstract][Full Text] [Related]
48. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
[TBL] [Abstract][Full Text] [Related]
49. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates.
Gentilini O; Botteri E; Veronesi P; Sangalli C; Del Castillo A; Ballardini B; Galimberti V; Rietjens M; Colleoni M; Luini A; Veronesi U
Ann Surg Oncol; 2012 Nov; 19(12):3771-6. PubMed ID: 22618719
[TBL] [Abstract][Full Text] [Related]
50. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
51. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.
Solin LJ; Hwang WT; Vapiwala N
Clin Breast Cancer; 2009 May; 9(2):96-100. PubMed ID: 19433390
[TBL] [Abstract][Full Text] [Related]
52. Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
Min SY; Lee SJ; Shin KH; Park IH; Jung SY; Lee KS; Ro J; Lee S; Kim SW; Kim TH; Kang HS; Cho KH
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e697-705. PubMed ID: 21129858
[TBL] [Abstract][Full Text] [Related]
53. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
54. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy.
Kaplan HG; Malmgren JA; Atwood M
Breast J; 2009; 15(5):454-60. PubMed ID: 19671105
[TBL] [Abstract][Full Text] [Related]
55. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
[TBL] [Abstract][Full Text] [Related]
56. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
[TBL] [Abstract][Full Text] [Related]
57. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
Mechera R; Viehl CT; Oertli D
Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
[TBL] [Abstract][Full Text] [Related]
58. [The clinical research of local recurrence after breast-conserving therapy for breast cancer].
Wang LZ; Ouyang T; Wang TF; Xie YT; Fan ZQ; Fan T; Lin BY; Li JF
Zhonghua Wai Ke Za Zhi; 2010 Dec; 48(24):1851-4. PubMed ID: 21211266
[TBL] [Abstract][Full Text] [Related]
59. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.
Hattangadi-Gluth JA; Wo JY; Nguyen PL; Abi Raad RF; Sreedhara M; Niemierko A; Freer PE; Georgian-Smith D; Bellon JR; Wong JS; Smith BL; Harris JR; Taghian AG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1185-91. PubMed ID: 21601377
[TBL] [Abstract][Full Text] [Related]
60. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
